Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
Clinical trial NCT03777657 · COMPLETED
Trial details
- NCT number
- NCT03777657
- Sponsor
- BeiGene
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-13
- Primary completion
- 2023-02-28
- Enrollment
- 997
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.